Tuberculosis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Tuberculosis – Pipeline Review, H2 2017’, provides an overview of the Tuberculosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Tuberculosis

The report reviews pipeline therapeutics for Tuberculosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Tuberculosis therapeutics and enlists all their major and minor projects

The report assesses Tuberculosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Tuberculosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Tuberculosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tuberculosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abera Bioscience AB

Akshaya Bio Inc

Archivel Farma SL

AstraZeneca Plc

Aucta Pharmaceuticals LLC

BioDiem Ltd

BioLingus AG

Bioversys AG

Celgene Corp

Chongqing Zhifei Biological Products Co Ltd

Consegna Pharma Inc

Crestone Inc

Daiichi Sankyo Co Ltd

Demuris Ltd

Eisai Co Ltd

Eli Lilly and Co

Ensol Biosciences Inc

EpiVax Inc

Evotec AG

FIT Biotech Oy

GangaGen Inc

GlaxoSmithKline Plc

Globeimmune Inc

Hager Biosciences LLC

Hsiri Therapeutics LLC

Immodulon Therapeutics Ltd

Immunitor Inc

ImmunoBiology Ltd

Inovio Pharmaceuticals Inc

Johnson & Johnson

Lakewood-Amedex Inc

LegoChem Biosciences Inc

Lipotek Pty Ltd

Matinas BioPharma Holdings Inc

Medivir AB

Merck & Co Inc

Microbion Corp

Microbiotix Inc

NEARMEDIC PLUS Ltd

Novartis AG

NovoBiotic Pharmaceuticals LLC

Otsuka Holdings Co Ltd

Pfizer Inc

QureTech Bio AB

Qurient Co Ltd

Recce Ltd

Rodos BioTarget GmbH

Sanofi

Sanofi Pasteur SA

Sequella Inc

Shionogi & Co Ltd

Spring Bank Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

Target Medicals LLC

Theravectys SA

TVAX Biomedical Inc

Vaccibody AS

Vakzine Projekt Management GmbH

Vaxil Bio Therapeutics Ltd

Vaxine Pty Ltd

Vichem Chemie Research Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Tuberculosis - Overview 7

Tuberculosis - Therapeutics Development 8

Tuberculosis - Therapeutics Assessment 32

Tuberculosis - Companies Involved in Therapeutics Development 43

Tuberculosis - Drug Profiles 70

Tuberculosis - Dormant Projects 324

Tuberculosis - Discontinued Products 332

Tuberculosis - Product Development Milestones 333

Appendix 344

List of Tables

List of Tables

Number of Products under Development for Tuberculosis, H2 2017 28

Number of Products under Development by Companies, H2 2017 30

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 31

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 32

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 33

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 34

Number of Products under Development by Universities/Institutes, H2 2017 35

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 37

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 38

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017 39

Products under Development by Companies, H2 2017 40

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 41

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 42

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 43

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 44

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 45

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 46

Products under Development by Universities/Institutes, H2 2017 47

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 48

Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 49

Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017 50

Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017 51

Number of Products by Stage and Target, H2 2017 53

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 54

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 55

Number of Products by Stage and Mechanism of Action, H2 2017 57

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 58

Number of Products by Stage and Route of Administration, H2 2017 60

Number of Products by Stage and Molecule Type, H2 2017 62

Tuberculosis – Pipeline by Abera Bioscience AB, H2 2017 63

Tuberculosis – Pipeline by Akshaya Bio Inc, H2 2017 63

Tuberculosis – Pipeline by Archivel Farma SL, H2 2017 64

Tuberculosis – Pipeline by AstraZeneca Plc, H2 2017 64

Tuberculosis – Pipeline by Aucta Pharmaceuticals LLC, H2 2017 65

Tuberculosis – Pipeline by BioDiem Ltd, H2 2017 65

Tuberculosis – Pipeline by BioLingus AG, H2 2017 65

Tuberculosis – Pipeline by Bioversys AG, H2 2017 66

Tuberculosis – Pipeline by Celgene Corp, H2 2017 66

Tuberculosis – Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2017 67

Tuberculosis – Pipeline by Consegna Pharma Inc, H2 2017 67

Tuberculosis – Pipeline by Crestone Inc, H2 2017 68

Tuberculosis – Pipeline by Daiichi Sankyo Co Ltd, H2 2017 68

Tuberculosis – Pipeline by Demuris Ltd, H2 2017 68

Tuberculosis – Pipeline by Eisai Co Ltd, H2 2017 69

Tuberculosis – Pipeline by Eli Lilly and Co, H2 2017 69

Tuberculosis – Pipeline by Ensol Biosciences Inc, H2 2017 70

Tuberculosis – Pipeline by EpiVax Inc, H2 2017 70

Tuberculosis – Pipeline by Evotec AG, H2 2017 71

Tuberculosis – Pipeline by FIT Biotech Oy, H2 2017 71

Tuberculosis – Pipeline by GangaGen Inc, H2 2017 72

Tuberculosis – Pipeline by GlaxoSmithKline Plc, H2 2017 72

Tuberculosis – Pipeline by Globeimmune Inc, H2 2017 73

Tuberculosis – Pipeline by Hager Biosciences LLC, H2 2017 73

Tuberculosis – Pipeline by Hsiri Therapeutics LLC, H2 2017 73

Tuberculosis – Pipeline by Immodulon Therapeutics Ltd, H2 2017 74

Tuberculosis – Pipeline by Immunitor Inc, H2 2017 74

Tuberculosis – Pipeline by ImmunoBiology Ltd, H2 2017 75

Tuberculosis – Pipeline by Inovio Pharmaceuticals Inc, H2 2017 75

Tuberculosis – Pipeline by Johnson & Johnson, H2 2017 76

Tuberculosis – Pipeline by Lakewood-Amedex Inc, H2 2017 76

Tuberculosis – Pipeline by LegoChem Biosciences Inc, H2 2017 76

Tuberculosis – Pipeline by Lipotek Pty Ltd, H2 2017 77

Tuberculosis – Pipeline by Matinas BioPharma Holdings Inc, H2 2017 77

Tuberculosis – Pipeline by Medivir AB, H2 2017 78

Tuberculosis – Pipeline by Merck & Co Inc, H2 2017 78

Tuberculosis – Pipeline by Microbion Corp, H2 2017 79

Tuberculosis – Pipeline by Microbiotix Inc, H2 2017 79

Tuberculosis – Pipeline by NEARMEDIC PLUS Ltd, H2 2017 79

Tuberculosis – Pipeline by Novartis AG, H2 2017 80

Tuberculosis – Pipeline by NovoBiotic Pharmaceuticals LLC, H2 2017 80

Tuberculosis – Pipeline by Otsuka Holdings Co Ltd, H2 2017 81

Tuberculosis – Pipeline by Pfizer Inc, H2 2017 81

Tuberculosis – Pipeline by QureTech Bio AB, H2 2017 82

Tuberculosis – Pipeline by Qurient Co Ltd, H2 2017 82

Tuberculosis – Pipeline by Recce Ltd, H2 2017 83

Tuberculosis – Pipeline by Rodos BioTarget GmbH, H2 2017 83

Tuberculosis – Pipeline by Sanofi, H2 2017 84

Tuberculosis – Pipeline by Sanofi Pasteur SA, H2 2017 84

Tuberculosis – Pipeline by Sequella Inc, H2 2017 85

Tuberculosis – Pipeline by Shionogi & Co Ltd, H2 2017 85

Tuberculosis – Pipeline by Spring Bank Pharmaceuticals Inc, H2 2017 86

Tuberculosis – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 86

Tuberculosis – Pipeline by Target Medicals LLC, H2 2017 86

Tuberculosis – Pipeline by Theravectys SA, H2 2017 87

Tuberculosis – Pipeline by TVAX Biomedical Inc, H2 2017 87

Tuberculosis – Pipeline by Vaccibody AS, H2 2017 87

Tuberculosis – Pipeline by Vakzine Projekt Management GmbH, H2 2017 88

Tuberculosis – Pipeline by Vaxil Bio Therapeutics Ltd, H2 2017 88

Tuberculosis – Pipeline by Vaxine Pty Ltd, H2 2017 89

Tuberculosis – Pipeline by Vichem Chemie Research Ltd, H2 2017 89

Tuberculosis – Dormant Projects, H2 2017 344

Tuberculosis – Dormant Projects, H2 2017 (Contd..1), H2 2017 345

Tuberculosis – Dormant Projects, H2 2017 (Contd..2), H2 2017 346

Tuberculosis – Dormant Projects, H2 2017 (Contd..3), H2 2017 347

Tuberculosis – Dormant Projects, H2 2017 (Contd..4), H2 2017 348

Tuberculosis – Dormant Projects, H2 2017 (Contd..5), H2 2017 349

Tuberculosis – Dormant Projects, H2 2017 (Contd..6), H2 2017 350

Tuberculosis – Dormant Projects, H2 2017 (Contd..7), H2 2017 351

Tuberculosis – Discontinued Products, H2 2017 352

List of Figures

List of Figures

Number of Products under Development for Tuberculosis, H2 2017 28

Number of Products under Development by Companies, H2 2017 29

Number of Products under Development by Universities/Institutes, H2 2017 35

Number of Products by Top 10 Targets, H2 2017 52

Number of Products by Stage and Top 10 Targets, H2 2017 52

Number of Products by Top 10 Mechanism of Actions, H2 2017 56

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 56

Number of Products by Routes of Administration, H2 2017 59

Number of Products by Stage and Routes of Administration, H2 2017 59

Number of Products by Top 10 Molecule Types, H2 2017 61

Number of Products by Stage and Top 10 Molecule Types, H2 2017 61

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports